| NFE2L2 — Nuclear Factor Erythroid 2-Related Factor 2 | |
|---|---|
| Symbol | NFE2L2 |
| Full Name | Nuclear Factor Erythroid 2-Related Factor 2 |
| Synonyms | Nrf2, NRF2, NFE2L2 |
| Chromosome | 2q31 |
| NCBI Gene | 4780 |
| OMIM | 604992 |
| Ensembl | ENSG00000116044 |
| UniProt | Q16236 |
| Protein | [NFE2L2 Protein](/proteins/nfe2l2-protein) |
| Gene Family | bZIP transcription factor family, Cap'n'collar subfamily |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), [Huntington's Disease](/diseases/huntingtons), Stroke |
NFE2L2 (Nuclear Factor Erythroid 2-Related Factor 2), commonly known as Nrf2, is a master transcriptional regulator of cellular antioxidant and cytoprotective responses. It is a basic leucine zipper (bZIP) transcription factor that controls the expression of a large network of antioxidant response element (ARE)-containing genes involved in detoxification, redox homeostasis, and stress resistance. Nrf2 is constitutively expressed in neurons and glia and plays a critical role in protecting the brain from oxidative stress, neuroinflammation, and protein aggregation—all hallmarks of neurodegenerative diseases.
The gene is catalogued as NCBI Gene ID 4780, OMIM 604992, and UniProt Q16236 [@kensler2007].
Nrf2 is the master regulator of the cellular antioxidant response. Under homeostatic conditions, Nrf2 is sequestered in the cytoplasm by Keap1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for ubiquitination and proteasomal degradation. Upon exposure to oxidative stress or electrophilic compounds, Nrf2 escapes Keap1-mediated repression, translocates to the nucleus, and heterodimerizes with small Maf proteins. This complex binds to ARE sequences in the promoter regions of target genes, driving their transcription [@talalay2007].
The Keap1-Nrf2 system functions as a molecular switch:
Nrf2 regulates over 200 target genes, including:
Nrf2 is expressed in all brain cell types [@jakel2007]:
Nrf2 activity declines with age and in AD brains. Amyloid-beta (Aβ) plaques and neurofibrillary tangles are associated with impaired Nrf2 signaling [@iizumi2016]:
Recent studies show Nrf2 deficiency exacerbates tau pathology, while Nrf2 activation protects against both amyloid and tau pathology [@chen2019; @bahar2023].
Nrf2 dysfunction contributes to dopaminergic neuron vulnerability in PD [@cule2022; @akanji2020]:
Studies show Nrf2 activation protects against alpha-synuclein toxicity, making it a promising therapeutic target [@vos2020].
Nrf2 signaling is impaired in ALS [@agostinone2021]:
Mutant huntingtin (mHTT) interferes with Nrf2 [@johansson2015]:
Nrf2 is neuroprotective in acute brain injury:
Nrf2 intersects with multiple pathways relevant to neurodegeneration [@liu2021; @sivandzade2019]:
Several NFE2L2 polymorphisms have been associated with neurodegenerative disease risk:
| Polymorphism | Effect | Disease Association |
|---|---|---|
| rs6721961 | Promoter variant | Reduced PD risk |
| rs4893823 | 3'UTR variant | Altered AD risk |
| rs1806649 | Coding variant | Variable effects |
Copy number variations and mutations in NFE2L2 have also been reported [@ramsey2007].
Nrf2 activators work primarily by modifying cysteine residues on Keap1, leading to Nrf2 release and nuclear translocation [@davarpanah2023; @brandle2023]:
| Compound | Mechanism | Clinical Status | References |
|---|---|---|---|
| Dimethyl fumarate (Tecfidera) | Covalent Keap1 modification | Approved for MS, trials for AD/PD | [@brandle2023] |
| Sulforaphane | Covalent Keap1 modification | Clinical trials for AD/PD | [@vos2020] |
| Bardoxolone methyl | Nrf2 activation via Keap1 | Clinical trials for CKD, AD | [@davarpanah2023] |
| Oltipraz | Nrf2 activation | Clinical trials for cancer, AD | - |
| Protandim | Nrf2 activation | Dietary supplement | - |
Recent drug development efforts focus on:
| Partner | Interaction Type | Function |
|---|---|---|
| KEAP1 | Direct binding | Cytoplasmic sequestration |
| small MAF proteins | Heterodimerization | DNA binding |
| p62/SQSTM1 | Phosphorylation feedback | Stabilization |
| CBP/p300 | Coactivator recruitment | Transcription |
| HDAC inhibitors | Epigenetic regulation | Enhanced expression |
| Bach1 | Competition | Transcriptional repression |